Americans seem to be increasingly attracted by a new ultrasound treatment for prostate cancer.
It is yet to be approved by the Food and Drug Administration (FDA), but people are willing to travel outside the country to undergo the operation and cough up huge money in the process.
The technique, called high-intensity focused ultrasound, or HIFU (pronounced HIGH-foo) attacks the cancerous tissue by heating the prostate to temperatures near boiling instead of the more traditional surgery or radiation.
Many travel across the borders to Mexico where a US-based firm is offering the treatment, which is incidentally approved in the European Union and Canada too.
But many cancer experts are skeptical. They argue that there is not yet enough evidence that the treatment stops cancer over the long run and they say the side effects are not as minimal as claimed.
The American Urological Association too says there is too little long-term data to evaluate HIFU.
The head of the prostate cancer program at Memorial Sloan-Kettering Cancer Center, Dr. Peter T. Scardino, said the procedure might prove useful for some special cases, but “for the treatment of the average ordinary prostate cancer, I think it’s a second-class form of therapy.”
Dr. Scardino is among prostate cancer experts concerned that when HIFU treatment preserves sexual potency, it is not eradicating the cancer.
The primary treatments for prostate cancer have an impotence rate approaching 50 percent, as well as a lesser risk of urinary incontinence.